Dosage form, process of making and using same
First Claim
Patent Images
1. A process for providing a controlled drug rate of release from a dosage form, wherein the dosage form comprises a composition, a dose of drug in the composition, and a hydrophilic polymer in the composition;
- and wherein the process comprises (1) formulating the composition with a drug possessing a size less than 150 μ
m, and (2) formulating the composition with a hydrophilic polymer of less than 250 μ
m size;
whereby, through the copresence of (1) and (2) in the composition, the drug is delivered at a controlled rate of release from the dosage form.
1 Assignment
0 Petitions
Accused Products
Abstract
The invention disclosed pertains to a dosage form comprising an agent formulation comprising drug and pharmaceutical carrier of cooperating particle size and means for dispensing the agent formulation from the dosage form.
-
Citations
31 Claims
-
1. A process for providing a controlled drug rate of release from a dosage form, wherein the dosage form comprises a composition, a dose of drug in the composition, and a hydrophilic polymer in the composition;
- and wherein the process comprises (1) formulating the composition with a drug possessing a size less than 150 μ
m, and (2) formulating the composition with a hydrophilic polymer of less than 250 μ
m size;
whereby, through the copresence of (1) and (2) in the composition, the drug is delivered at a controlled rate of release from the dosage form. - View Dependent Claims (2, 3)
- and wherein the process comprises (1) formulating the composition with a drug possessing a size less than 150 μ
-
4. A process for providing a controlled drug rate of release from a dosage form, wherein the dosage form comprises:
- a drug composition comprising a dose of drug and a hydrophilic polymer, and a dispensing, composition comprising means for dispensing the drug composition from the dosage form; and
wherein the process comprises formulating the drug composition with a drug possessing a particle size up to 150 μ
m and with a hydrophilic polymer possessing a particle size up to 250 μ
m, which, through the cooperation of the drug particles and the hydrophilic polymer particles, and the dispensing composition assisting the drug composition, the drug is delivered at a substantially controlled rate of release from the dosage form. - View Dependent Claims (5, 6, 7, 8)
- a drug composition comprising a dose of drug and a hydrophilic polymer, and a dispensing, composition comprising means for dispensing the drug composition from the dosage form; and
-
9. A dosage form for the delivery of a drug, wherein the dosage form comprises:
-
(a) a composition comprising; (b) a dose of drug in the composition said drug comprising a size less than 150 μ
m;(c) a hydrophilic polymer in the composition, said polymer comprising a size less than 250 μ
m;(d) a wall comprising a composition permeable to the passage of fluid that surrounds the composition comprising the dose of drug and the hydrophilic polymer; and (e) means in the wall for delivering the drug at a substantially controlled rate from the dosage form.
-
-
10. A dosage form for the delivery of a drug, wherein the dosage form comprises
(a) a drug composition; -
(b) a dose of drug comprising a size of less than 150 μ
m in the drug composition;(c) a hydrophilic polymer comprising a size of less than 250 μ
m in the drug composition;(d) a coat that surrounds the drug composition comprising means for delaying release of drug from the drug composition; (e) a wall comprising a composition that surrounds the coat; and
,(f) means in the dosage form for delivering the drug from the dosage form. - View Dependent Claims (11)
-
-
12. A dosage form for the delivery of a drug, wherein the dosage form comprises:
-
(a) a drug composition comprising a drug comprising a particle of less than 150 μ
m size and a pharmaceutically acceptable hydrophilic polymer carrier comprising a particle of less than 250 μ
m size;(b) a displacement composition in contact with the drug composition comprising means for causing fluid to enter the displacement composition, whereby the displacement composition increases in volume and displaces the drug composition from the dosage form; (c) a wall, comprising means for permitting a fluid to enter the dosage form, that surrounds the drug composition and the displacement composition; and (d) means in the wall for delivering the drug as a substantially constant rate over a dispensing time. - View Dependent Claims (13)
-
-
14. A dosage form for delivering a drug orally to a patient in need of a drug, wherein the dosage form comprises:
-
(a) a drug composition comprising a drug comprising a particle size up to and including 150 μ
m, and a hydrophilic polymer carrier for the drug comprising a particle size up to and including 250 μ
m;(b) a displacement composition in contrast with the drug composition comprising a polymer that expands in the presence of fluid for displacement of the drug composition from the dosage form; (c) a coat, free of drug, which surrounds the drug and the displacement composition for slowing the passageway of fluid into the dosage form; (d) a wall tha surrounds the coat and is permeable to the passage of fluid; and
,(e) means in the dosage form for delivering the drug from the dosage form at a substantially constant rate over time. - View Dependent Claims (15, 16)
-
-
17. A method for the management of blood pressure in a patient, wherein the method comprises:
-
(a) admitting orally into the patent a therapeutic composition comprising a dose of drug indicated for the management of blood pressure with the drug possessing a particle size of less than 150 μ
m, and a pharmaceutically acceptable hydrophilic carrier for the drug possessing a particle size of less than 250 μ
m; and
,(b) managing the blood pressure by codelivering the drug and the accompanying polymer at a substantially constant rate of release from the composition to provide an effective dose for managing the blood pressure of the patient. - View Dependent Claims (18, 19, 20)
-
-
21. A method for the management of the systemic physiology of a patient, wherein the method comprises:
-
(a) admitting orally into the patient a therapeutic composition comprising a dose of drug indicated for the management of a systemic physiology with the drug possessing an average particle size of less than 150 μ
m, and a therapeutically acceptable hydrophilic polymer possessing an average particle size of less than 250 μ
m for delivering the drug from the therapeutic composition; and
a delivery composition in contact with the therapeutic composition comprising a therapeutically acceptable hydrophilic polymer possessing a greater number-average molecular weight than the hydrophilic polymer present in the therapeutic composition for aiding in delivering the drug from the therapeutic composition; and
,(b) managing the systemic physiology of the patient by the codelivery of the drug and the polymer at a substantially constant rate of release from the therapeutic composition aided by the delivery composition to provide an effective dose for the management of the systemic physiology of the patient. - View Dependent Claims (22, 23, 24, 25)
-
-
26. A method of timetherapy for delivering a drug to a patient at a selected time, wherein the method comprises administering orally to the patient a therapeutic composition comprising a dose of drug possessing an average particle size up to 150 μ
- m and a pharmaceutically acceptable polymer possessing an average particle size up to 250 μ
m, and means for governing the release of drug from the therapeutic composition, whereby the drug is released by the means in a substantially constant rate of release at the selected time for timetherapy.
- m and a pharmaceutically acceptable polymer possessing an average particle size up to 250 μ
-
27. A method for timetherapy for delivering a drug to a patient over a selected time for the management of hypertension, wherein the method comprises orally administering to the patient a therapeutic composition comprising a calcium channel blocker drug and an angiotensin converting enzyme inhibitor drug possessing an average particle size up to 150 μ
- m and a pharmaceutically acceptable polymer possessing an average particle size up to 250 μ
m, and means for governing the release of the drugs from the therapeutic composition, whereby the drugs are timed-release in a substantially constant dose over the selected time for the timetherapy management of hypertension. - View Dependent Claims (28, 29, 30, 31)
- m and a pharmaceutically acceptable polymer possessing an average particle size up to 250 μ
Specification